Comparison of Canagliflozin, Dapagliflozin and Empagliflozin Added to Heart Failure Treatment in Decompensated Heart Failure Patients With Type 2 Diabetes Mellitus

Background: Three sodium-glucose cotransporter-2 inhibitors (SGLT2i), canagliflozin, dapagliflozin and empagliflozin, successfully reduced hospitalization for heart failure (HF) in patients with type 2 diabetes mellitus (T2DM). It remains unclear, however, whether the efficacy of the 3 SGLT2i for HF...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakagaito, Masaki, Joho, Shuji, Ushijima, Ryuichi, Nakamura, Makiko, Kinugawa, Koichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Circulation Society 2019
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897568/
https://www.ncbi.nlm.nih.gov/pubmed/33693077
http://dx.doi.org/10.1253/circrep.CR-19-0070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897568/
https://www.ncbi.nlm.nih.gov/pubmed/33693077
http://dx.doi.org/10.1253/circrep.CR-19-0070

Ejemplares similares